These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 29689646)

  • 21. The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy.
    Fujioka K; Plodkowski R; O'Neil PM; Gilder K; Walsh B; Greenway FL
    Int J Obes (Lond); 2016 Sep; 40(9):1369-75. PubMed ID: 27328752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes.
    Apovian CM
    Future Cardiol; 2016 Mar; 12(2):129-38. PubMed ID: 26679384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness and persistence of anti-obesity medications (liraglutide 3 mg, lorcaserin, and orlistat) in a real-world primary care setting.
    Leventhal-Perek S; Shani M; Schonmann Y
    Fam Pract; 2023 Dec; 40(5-6):629-637. PubMed ID: 36477550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contrave--a combination of bupropion and naltrexone for weight loss.
    Med Lett Drugs Ther; 2014 Nov; 56(1455):112-4. PubMed ID: 25372849
    [No Abstract]   [Full Text] [Related]  

  • 25. Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity.
    Ali KF; Shukla AP; Aronne LJ
    Expert Rev Clin Pharmacol; 2016; 9(1):27-34. PubMed ID: 26512740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Routine clinical use of liraglutide 3 mg for the treatment of obesity: Outcomes in non-surgical and bariatric surgery patients.
    Suliman M; Buckley A; Al Tikriti A; Tan T; le Roux CW; Lessan N; Barakat M
    Diabetes Obes Metab; 2019 Jun; 21(6):1498-1501. PubMed ID: 30768836
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Obesity Services in Public Hospitals in Australia: a position statement based on expert consensus.
    Atlantis E; Kormas N; Samaras K; Fahey P; Sumithran P; Glastras S; Wittert G; Fusco K; Bishay R; Markovic T; Ding L; Williams K; Caterson I; Chikani V; Dugdale P; Dixon J
    Clin Obes; 2018 Jun; 8(3):203-210. PubMed ID: 29683555
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An update on pharmacotherapeutic strategies for obesity.
    Tchang BG; Tarazi MS; Aras M; Shukla AP
    Expert Opin Pharmacother; 2021 Jul; 22(10):1305-1318. PubMed ID: 33599159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Total and H-specific growth/differentiation factor 15 levels are unaffected by liraglutide or naltrexone/bupropion administration.
    Konstantinidou SK; Argyrakopoulou G; Simati S; Stefanakis K; Kokkinos A; Analitis A; Mantzoros CS
    Diabetes Obes Metab; 2024 Aug; 26(8):3147-3154. PubMed ID: 38757729
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient-reported quality of life in a randomized placebo-controlled trial of naltrexone/bupropion for obesity.
    Kolotkin RL; Chen S; Klassen P; Gilder K; Greenway FL
    Clin Obes; 2015 Oct; 5(5):237-44. PubMed ID: 26222044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of anti-obesity medications in people with mental illness as an adjunct to lifestyle interventions - Effectiveness, tolerability and impact on eating behaviours: A 52-week observational study.
    Tham M; Chong TWH; Jenkins ZM; Castle DJ
    Obes Res Clin Pract; 2021; 15(1):49-57. PubMed ID: 33257207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Five-year Weight Loss Maintenance With Obesity Pharmacotherapy.
    Weintraub MA; D'Angelo D; Tchang BG; Sahagun AD; Andre C; Aronne LJ; Shukla AP
    J Clin Endocrinol Metab; 2023 Aug; 108(9):e832-e841. PubMed ID: 36810608
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reducing the risk of obesity: defining the role of weight loss drugs.
    Ling H; Lenz TL; Burns TL; Hilleman DE
    Pharmacotherapy; 2013 Dec; 33(12):1308-21. PubMed ID: 23712541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Naltrexone extended-release plus bupropion extended-release for treatment of obesity.
    Yanovski SZ; Yanovski JA
    JAMA; 2015 Mar 24-31; 313(12):1213-4. PubMed ID: 25803343
    [No Abstract]   [Full Text] [Related]  

  • 35. Miracle pills for weight loss: what is the number needed to treat, number needed to harm and likelihood to be helped or harmed for naltrexone-bupropion combination?
    Citrome L
    Int J Clin Pract; 2010 Oct; 64(11):1462-1465. PubMed ID: 20846190
    [No Abstract]   [Full Text] [Related]  

  • 36. Management of obesity.
    Bray GA; Frühbeck G; Ryan DH; Wilding JP
    Lancet; 2016 May; 387(10031):1947-56. PubMed ID: 26868660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacologic therapies for obesity.
    Kaplan LM
    Gastroenterol Clin North Am; 2010 Mar; 39(1):69-79. PubMed ID: 20202580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
    Verpeut JL; Bello NT
    Expert Opin Drug Saf; 2014 Jun; 13(6):831-41. PubMed ID: 24766397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Medications for weight loss.
    Mordes JP; Liu C; Xu S
    Curr Opin Endocrinol Diabetes Obes; 2015 Apr; 22(2):91-7. PubMed ID: 25692921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of commissioning weight-loss surgery for bariatric patients.
    Petty N
    Br J Nurs; 2015 Aug 13-Sep 19; 24(15):776-80. PubMed ID: 26266444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.